Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3

Withdrawn

Conditions: Carcinoma, Non-small Cell Lung

Interventions: Drug: EFG816
Drug: erlotinib or gefitinib

First Posted Date: 2018-05-18

Last Posted Date: 2019-11-22

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03529084

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Phase 4

Completed

Conditions: Renal Angiomyolipoma

Interventions: Drug: Everolimus

First Posted Date: 2018-05-16

Last Posted Date: 2021-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03525834

Locations: 🇨🇳
Novartis Investigative Site, Beijing, China

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

Phase 2

Completed

Conditions: Immune Thrombocytopenic Purpura (ITP)

Interventions: Drug: eltrombopag

First Posted Date: 2018-05-15

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT03524612

Locations: 🇺🇸
Hematology Oncology Association of Rockland, Nyack, New York, United States
🇺🇸
Case Western Reserve, Cleveland, Ohio, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis

Phase 2

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: Tropifexor (LJN452)
Drug: Cenicriviroc (CVC)

First Posted Date: 2018-05-07

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 193

Registration Number: NCT03517540

Locations: 🇬🇧
Novartis Investigative Site, Torquay, United Kingdom

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: ZPL389 50mg
Drug: ZPL389 10mg
Drug: Placebo
Drug: ZPL389 3mg
Drug: ZPL389 30mg

First Posted Date: 2018-05-07

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 293

Registration Number: NCT03517566

Locations: 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Placebo
Drug: Midostaurin
Drug: Chemotherapy

First Posted Date: 2018-04-30

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 511

Registration Number: NCT03512197

Locations: 🇺🇸
University of Chicago Medical Center ., Chicago, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Oregon Health and Science Univ, Portland, Oregon, United States

and more 1 locations

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis

Interventions: Drug: secukinumab 150 mg

First Posted Date: 2018-04-20

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 331

Registration Number: NCT03504852

Locations: 🇷🇺
Novartis Investigative Site, Saratov, Russian Federation

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Phase 2

Completed

Conditions: Triple-negative Breast Cancer

Interventions: Drug: LAG525
Drug: PDR001
Drug: Carboplatin

First Posted Date: 2018-04-17

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT03499899

Locations: 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇹🇭
Novartis Investigative Site, Songkla, Thailand
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States

Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne

Phase 2

Completed

Conditions: Inflammatory Acne

Interventions: Drug: LYS006 2 mg
Drug: Placebo
Drug: LYS006 20 mg

First Posted Date: 2018-04-13

Last Posted Date: 2023-08-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT03497897

Locations: 🇳🇱
Novartis Investigative Site, Nijmegen, Netherlands

Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease

Phase 1

Completed

Conditions: Acute Graft Versus Host Disease

Interventions: Drug: Ruxolitinib

First Posted Date: 2018-04-09

Last Posted Date: 2024-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03491215

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy